Discover Enhanced Combinations
Discover preclinical differences in bispecific impact on T cell & tumor cell interactions1
Detect potent functional immune cell subsets to accelerate preclinical decision making.
Identify subtle differences and mechanism in therapies that engage T cells and the tumor microenvironment
PSI revealed differences to enhance decision making
Enhanced bispecifics elicit more polyfunctional subsets than control when interacting with tumor target
PSI identified T cell potency upregulation triggered by novel bispecifics and revealed unique T cell cytokine mechanisms in response to tumor target. PSI was computed for CD4+ and CD8+ T cells; the profiles of both B2-OKT3 and hNKG2D-OKT3 showed significant polyfunctional upregulation relative to the Tz47-2C11 control sample, indicating their effectiveness in triggering a potent T cell response.
Both bispecific profiles are dominated by effector cytokines. hNKG2G-OKT3 stimulation is more potent in terms of polyfunctional strength index (PSI) than B2-OKT3, and sources of upregulation are revealed through the differential cytokine profile (i.e. chemoattractive and effector cytokines). CD4+ and CD8+ cells show the same trend and almost identical cytokine secretion with the exception of IL-5.1